This federal contract award, valued at $16,163.90, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract to supply the medication Dupixent 300 mg/2 ml pen with an ultimate completion date of December 9, 2024.
Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. Additionally, Amerisourcebergen maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.
This specific contract award was not designated with a set-aside requirement, indicating open competition. The award demonstrates Amerisourcebergen's role as a key vendor for federal healthcare programs, particularly within military and veterans' healthcare systems, through its extensive supply chain and distribution capabilities.
Generated 3/7/25, 9:42 AM